EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische StudieRandomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Effects of Resmetirom on Metabolic‐Dysfunction Associated Steatohepatitis in Patients With Weight Loss and/or Diabetes Taking Glucagon‐Like Peptide‐1 Receptor Agonists and Other Diabetes Therapies: A Secondary Analysis of the MAESTRO ‐ NASH Trial

Mazen Noureddin, Mary Rinella, Rebecca Taub, Dominic Labriola, Raul C Camacho, Naim Alkhouri iD, Rohit Loomba iD, Meena B Bansal iD

Alimentary Pharmacology & Therapeutics · 2025-12 · 62 (11-12) · 1089-1099

DOI: 10.1111/apt.70382 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Alimentary Pharmacology & Therapeutics, online erschienen am 23.10.2025. Verfasst von Mazen Noureddin und 7 weiteren Autor:innen. Beteiligte Einrichtung: Houston Methodist Hospital, Houston, Texas, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Fatty Liver, Glucagon-Like Peptide-1 Receptor Agonists, Hypoglycemic Agents. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Madrigal Pharmaceuticals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

MAESTRO‐NASH, a randomised, double‐blind, placebo‐controlled, 54‐month phase 3 trial evaluating the efficacy of resmetirom in patients with biopsy‐confirmed metabolic‐dysfunction associated steatohepatitis (MASH) and liver fibrosis achieved primary endpoints of MASH resolution with no worsening of fibrosis, and ≥ 1‐stage improvement in fibrosis with no worsening of MASH at 52‐weeks.

Aims

The effects of resmetirom (80 or 100 mg) versus placebo were evaluated on Week 52 histological and biomarker endpoints in relation to background treatment with sodium‐glucose cotransporter 2 inhibitors (SGLT2i), GLP‐1 receptor agonists (GLP‐1 RA), and/or ≥ 5% weight loss at Week 52.

Methods

At baseline, 13%–17% of patients (all with type 2 diabetes mellitus [T2DM]) were on stable GLP‐1 RA or SGLT2i therapy. Changes in liver histology, MRI‐proton density fat fraction (MRI‐PDFF), and liver stiffness were examined after 52 weeks of treatment.

Results

No weight loss above baseline occurred with GLP‐1 RA or SGLT2i therapy. SGLT2 and GLP‐1 RA treated patients showed similar rates of MASH resolution and fibrosis improvement in combination with resmetirom as patients not on these therapies. Resmetirom‐treated patients (100 mg) with weight loss (≥ 5%) compared with those with weight loss < 5% had higher rates of MASH resolution (56.6% vs. 33.8%), fibrosis improvement (40.6% vs. 31.5%), MRI‐PDFF reduction (−69% vs. −46%), and liver stiffness reduction after 52 weeks of treatment (−4.6 kPa vs. −2.3 kPa).

Conclusions

The efficacy of resmetirom on multiple MASH endpoints was not impacted by background SGLT2i or GLP‐1 RA treatment. Weight loss (≥ 5%) enhanced the efficacy of resmetirom. Trial Registration MAESTRO‐NASH ClinicalTrials.gov number, NCT03900429

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Fatty LiverGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsNon-alcoholic Fatty Liver DiseaseWeight LossAdultAgedFemaleHumansMaleMiddle AgedDouble-Blind MethodLiver CirrhosisSodium-Glucose Transporter 2 InhibitorsTreatment Outcome

Stichwörter der Autor:innen

GLP‐1 receptor agonistsMASH resolutionfibrosis improvementresmetiromweight loss

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsSodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Houston Methodist Hospital, Houston, Texas, USA.
  • Houston Research Institute, Houston, Texas, USA.
  • University of Chicago, Pritzker School of Medicine, Chicago, Illinois, USA.
  • Madrigal Pharmaceuticals, West Conshohocken, Pennsylvania, USA.
  • Summit Clinical Research, San Antonio, Texas, USA.
  • MASLD Research Center, University of California at San Diego, La Jolla, California, USA.

ORCID-Profile: Naim Alkhouri, Rohit Loomba, Meena B Bansal

Förderung

  • Madrigal Pharmaceuticals

Zitieren

APA

Noureddin, M., Rinella, M., Taub, R., Labriola, D., Camacho, R. C., Alkhouri, N., Loomba, R., & Bansal, M. B. (2025). Effects of Resmetirom on Metabolic‐Dysfunction Associated Steatohepatitis in Patients With Weight Loss and/or Diabetes Taking Glucagon‐Like Peptide‐1 Receptor Agonists and Other Diabetes Therapies: A Secondary Analysis of the MAESTRO ‐ NASH Trial. Alimentary Pharmacology & Therapeutics, 62(11-12), 1089-1099. https://doi.org/10.1111/apt.70382

Vancouver

Noureddin M, Rinella M, Taub R, Labriola D, Camacho RC, Alkhouri N, et al. Effects of Resmetirom on Metabolic‐Dysfunction Associated Steatohepatitis in Patients With Weight Loss and/or Diabetes Taking Glucagon‐Like Peptide‐1 Receptor Agonists and Other Diabetes Therapies: A Secondary Analysis of the MAESTRO ‐ NASH Trial. Alimentary Pharmacology & Therapeutics. 2025;62(11-12):1089-1099. doi:10.1111/apt.70382

BibTeX
@article{Noureddin2025,
  author = {Noureddin, Mazen and Rinella, Mary and Taub, Rebecca and Labriola, Dominic and Camacho, Raul C and Alkhouri, Naim and Loomba, Rohit and Bansal, Meena B},
  title = {Effects of Resmetirom on Metabolic‐Dysfunction Associated Steatohepatitis in Patients With Weight Loss and/or Diabetes Taking Glucagon‐Like Peptide‐1 Receptor Agonists and Other Diabetes Therapies: A Secondary Analysis of the MAESTRO ‐ NASH Trial},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2025},
  volume = {62},
  number = {11-12},
  pages = {1089--1099},
  doi = {10.1111/apt.70382}
}
Kostenlos starten →